Evaluation and Treatment of Vulvodynia: State of the Science

Vulvodynia is a chronic vulvar pain condition of unknown cause that affects approximately 7% of American women, causing severe impact on quality of life and intimate relationships. This comprehensive state-of-the-science review examined 41 studies to evaluate the efficacy of various treatments for vulvodynia, ranging from topical therapies to surgical interventions. The findings reveal that there are eight treatments with the highest level of scientific evidence, including multimodal physical therapy, acupuncture, intravaginal transcutaneous electrical nerve stimulation, 5% overnight lidocaine ointment, oral desipramine with 5% lidocaine cream, vaginal diazepam tablets with electrical stimulation, type A botulinum toxin injections, and subcutaneous enoxaparin sodium injections. Acupuncture, specifically, demonstrated promising results in a randomized clinical trial, significantly reducing vulvar pain from 5.6 to 2.7 on a 0-10 scale and improving dyspareunia compared with usual care.

The acupuncture treatment followed a standardized protocol with needling in the abdomen, suprapubic region, and extremities, but not directly on the vulva, based on the traditional Chinese medicine theory of unblocking qi. The physiological mechanisms of acupuncture include increased release of mu-opioids and beta-endorphins, important in reducing pain sensation. The review methodology analyzed studies ranging from case series to randomized clinical trials, using the evidence classification system from the University of Oxford Centre for Evidence-Based Medicine. The results show wide variability in treatments prescribed for vulvodynia, with the National Vulvodynia Registry documenting 78 different treatments prescribed for 282 women, with 72% receiving more than one treatment.

This diversity reflects the complexity of the condition and the need for individualized approaches. Non-pharmacologic and minimally invasive therapies, such as multimodal physical therapy and acupuncture, proved particularly valuable as first-line treatments. Multimodal physical therapy — which includes education, pelvic floor exercises with biofeedback, manual therapy, and dilation — demonstrated significant superiority compared with topical lidocaine in a large multicenter clinical trial. Topical treatments, including lidocaine, gabapentin, and amitriptyline, offer the advantage of local action with minimal systemic absorption.

Significant limitations identified include the scarcity of high-quality randomized clinical trials with large samples, lack of standardization in pain and dyspareunia measures across studies, and absence of direct comparisons between multiple treatment modalities. Many studies lack adequate control groups, making it difficult to determine true therapeutic efficacy. The heterogeneity of the studies and small sample sizes limit the validity, rigor, reproducibility, and generalizability of the results. The clinical implications suggest that clinicians should prioritize treatments with stronger scientific evidence and lower invasiveness, considering that the etiology of vulvodynia remains unknown, making evidence-based empirical treatment the best current approach.